(1). PDGF/VEGF targeting in treating ocular neovascular diseases. Neovascular complication in the eye is the major cause of blindness in the old population and the Western society. Many angiogenesis inhibitors have been tested for treating such diseases, and beneficial effects have been demonstrated. Yet, the progression of such pathologies cannot be halted or reversed. Studies characterizing new molecules playing important roles in ocular neovascularization are therefore awaited. Ongoing work in our unit is investigating the angiogenic activity of the PDGFs/VEGFs in ocular neovascularization and the potential of PDGF/VEGF targeting in treating ocular vascular diseases. (2). Neuroprotection by growth factors in retinal neurodegenerative diseases. Neurodegeneration occurs in many types of ocular diseases. Numerous factors contribute to such diseases and there is currently no general treatment effective for all forms of retinal degeneration. Neuroprotection as achieved by neurotrophic/survival factors has emerged to be one general strategy for the treatment of such pathologies. However, the number of such neuroprotective factors is still limited. We are currently using multiple approaches including protein delivery, gene and cell therapy, normal and transgenic mice, in combination with other loss-of-function studies to investigate the neuroprotective effect of several growth factors in treating retinal neurodegenerative diseases. (3). Effect of PDGFs/VEGFs on retinal stem cells and retinal development. Cell therapy using eye stem cells is one of the most promising therapeutic approaches to treat retinal neurodegenerative diseases. However, it is yet not well understood how the eye stem cells are regulated. A better understanding into this aspect is warranted. We are currently using multiple approaches, such as protein/gene delivery and transgenic mice for gain of function studies, and RNAi/neutralizing antibodies and the gene deficient mice for loss of function studies, to investigate the role of the PDGFs/VEGFs in ocular stem cell proliferation/differentiation and retinal development.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAEY000447-03
Application #
7968381
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2009
Total Cost
$1,347,483
Indirect Cost
Name
U.S. National Eye Institute
Department
Type
DUNS #
City
State
Country
Zip Code
Li, Xuri; Kumar, Anil; Zhang, Fan et al. (2012) Complicated life, complicated VEGF-B. Trends Mol Med 18:119-27
Hou, Xu; Hu, Dan; Wang, Yu-sheng et al. (2012) Targeting of junctional adhesion molecule-C inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 53:1584-91
Langer, Harald F; Choi, Eun Young; Zhou, Hong et al. (2012) Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 110:1202-10
Tang, Zhongshu; Zhang, Fan; Li, Yang et al. (2011) A mouse model of the cornea pocket assay for angiogenesis study. J Vis Exp :
Tang, Zhongshu; Zhang, Shuihua; Lee, Chunsik et al. (2011) An optic nerve crush injury murine model to study retinal ganglion cell survival. J Vis Exp :
Hou, Xu; Kumar, Anil; Lee, Chunsik et al. (2010) PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. Proc Natl Acad Sci U S A 107:12216-21
Li, Xuri (2010) VEGF-B: a thing of beauty. Cell Res 20:741-4
Tang, Zhongshu; Arjunan, Pachiappan; Lee, Chunsik et al. (2010) Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. J Exp Med 207:867-80
Kumar, Anil; Hou, Xu; Lee, Chunsik et al. (2010) Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation. J Biol Chem 285:15500-10
Narazaki, Masashi; Segarra, Marta; Hou, Xu et al. (2010) Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis. Blood 116:3099-107

Showing the most recent 10 out of 19 publications